HEOR, RWE and Market Access
Welcome to the HEOR, RWE and Market Access knowledge hub.
As healthcare moves towards decision-making driven by evidence and value, there is increased demand for health economics outcomes research (HEOR), real world data (RWD), real world evidence (RWE) and market access capabilities. Scientist.com streamlines the sourcing of these services by increasing your ability to utilize the best solution providers, reducing time to contract and enabling quicker time to insight, all of which improve patient and market access.
Popular Services Click here for a full list
HEOR, RWE and Market Access Features
At Scientist.com, you can now access hundreds of suppliers of HEOR, RWE/RWD and Market Access services, with this number increasing monthly. By using our category-specific RFI, biopharma buyers can more easily and confidently identify suppliers with the desired capabilities, subject matter expertise or data access to meet specific needs.
Scientist.com has also expanded the number of Real World Data providers as well as firms with value communication expertise, thereby complementing our established areas of RWE, Health Economics and Market Access.
Resources from HealthEconomics.com – a Scientist.com company:
In 2020, Scientist.com completed the acquisition of our longtime partner HealthEconomics.com to support the growing demand for HEOR, RWE and Market Access services. They are the world’s largest digital CONNECTED COMMUNITY™ that provides a single global link to the health economic and outcomes research (HEOR), real-world evidence (RWE), and Market Access (MA) stakeholder communities.
Resources available from HealthEconomics.com include:
- tHEORetically Speaking Blog – the official blog of HealthEconomics.com
- Industry White Papers
- Syndicated Reports
- Conferences
- Webinars
- Industry News (RSS)
HealthEconomics.com News Feed
HealthEconomics.comSenate Excludes Orphan Cures Act from Trump’s Tax Bill, Impacting BiopharmaThe Senate's exclusion of the Orphan Cures Act from Trump's tax bill, aimed at incentivizing rare disease drug development, sparks debate between biopharma advocates and drug price reduction proponents. The post Senate Excludes Orphan Cures Act from Trump’s Tax Bill, Impacting Biopharma appeared first on HealthEconomics.com. Bayer Innovation Procurement Expands Use of AI Platform to Streamline Clinical and RWE ProcurementScientist.com’s platform is expanding to support Bayer across the entire R&D value chain, including clinical and RWE operations with guided buying, compliance tracking, and AI-powered sourcing tools. The post Bayer Innovation Procurement Expands Use of AI Platform to Streamline Clinical and RWE Procurement appeared first on HealthEconomics.com. Leveraging Statistical Data Monitoring to Detect Fraud in Clinical TrialsExplore how statistical data monitoring can uncover data integrity issues in clinical trials, focusing on the detection of fraud and sloppiness. Learn about the pivotal role of statistical tests in ensuring compliance with ICH E6 (R3) guidelines for research integrity. The post Leveraging Statistical Data Monitoring to Detect Fraud in Clinical Trials appeared first on HealthEconomics.com. |
Media and News Center
This installment was written by xCures, whose mission is to improve cancer outcomes using A.I. and predictive modeling. With the explosion of AI...
On September 21, Scientist.com and speakers from PRECISIONheor, PRMA Consulting and OpenHealth participated in the second episode of the Cutting...
Scientist.com, the parent company of HealthEconomics.Com, recently announced the newly rebranded Value, Evidence and Access Marketplace – an online...